Rheumatology

NICE appraisal of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis

The National Institute for Health and Clinical Excellence (NICE) has today (24 October) published final guidance on the use of the tumour necrosis factor alpha (TNF-?) inhibitors adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis.
Read more

 http://www.nice.org.uk/page.aspx?o=461255...

National Institute for Health and Clinical Excellence